Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘mesothelioma’

The World Conference on Lung Cancers (WCLC) annual meeting in Singapore showcased important scientific findings illuminating new directions against these deadly diseases.

While some clinical presentations fell a little short of expectations, smaller sessions revealed some important gems illustrating the intricacies of lung cancer biology where art and science intersect.

In the end lung cancer remains complex, heterogeneous, often aggressive, and evolving. Emerging translational research undoubtedly brings hope towards guiding more targeted therapeutic strategies.

The art is in creatively leveraging emerging science to tackle these lethal diseases from every angle.

Here we highlight seven areas where we ought to be paying attention to when considering future directions in lung cancer…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Gah, if only we hadn’t enrolled allcomers in our study, the differences would have been so much bigger!

Barcelona – This is the day when many people get absolutely walloped by exhaustion at ESMO even after three double espressos – if you’re still going strong then I commend your stamina and fortitude!

This is a big day for several companies with important phase 3 trial readouts due to be presented at the conference today.

One in particular is the phase 3 PROfound trial exploring the role of the PARP inhibitor, olaparib, in HRD+ advanced prostate cancer.

Beyond the top line findings (the PFS endpoint was met) there are a LOT of subtleties and nuances to consider so we have an analysis to share of some of the pitfalls and potential issues that may be missed in the hurly burly and noise.

Are you ready?

There’s a lot to think about today, not just in PROfound, but also quite a few other studies have been put under the microscope too.

Here we go unto the breach, my friends…

To learn more from our latest oncology conference insights and get a heads up on our latest ESMO Coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!